Physician profile
Steven A Culbert
NPI 1619904000
$1,769.26
in general payments reported to CMS, 2019-2025
28 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $67.20 · 2021: $239 · 2022: $297 · 2023: $390 · 2024: $186 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $201.36 | 2019-2025 | Veozah |
| Abbvie INC. | $199.44 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $164.88 | 2019-2025 | |
| Pfizer INC. | $114.58 | 2019-2024 | |
| Hologic Sales and Service, LLC | $103.08 | 2021-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Acessa Provu System |
| Evofem Biosciences, INC. | $89.36 | 2021-2025 | Phexxi, Solosec, Phexx |
| Mayne Pharma Commercial LLC | $86.86 | 2022-2025 | |
| Myriad Women'S Health, INC. | $80.22 | 2023 | Myrisk |
| Exeltis, USA INC. | $74.54 | 2022-2023 | Slynd |
| Sumitomo Pharma America, INC. | $71.68 | 2023-2024 | Myfembree |
| Exact Sciences Corporation | $63.86 | 2023-2024 | Cologuard Collection Kit |
| Coopersurgical, INC. | $63.41 | 2019-2023 | Paragard T 380a, Advincula Delineator Uterine Manipulator |
| Daiichi Sankyo INC. | $56.61 | 2021-2023 | Injectafer |
| Myovant Sciences INC. | $48.36 | 2022 | |
| Organon LLC | $45.03 | 2021-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics Corporation | $37.84 | 2019 | |
| Medtronic, INC. | $36.20 | 2022 | |
| Millicent US INC | $32.70 | 2019-2025 | Intrarosa |
| Amag Pharmaceuticals, INC. | $27.75 | 2019 | |
| Merck Sharp & Dohme LLC | $27.59 | 2019-2020 | |
| Agile Therapeutics, INC. | $26.63 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.90 | 2025 | Vpriv |
| Sage Therapeutics, LLC | $18.71 | 2025 | Zurzuvae |
| Smith+Nephew, INC. | $18.32 | 2024 | Pico 7 |
| Amgen INC. | $15.60 | 2023 | Prolia, Evenity |
| Alydia Health | $14.79 | 2021 | |
| Therapeuticsmd, INC. | $14.74 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Culbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.